| Bioactivity | Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research[1]. |
| Target | IC50: 11.1 nM (human FXa) |
| In Vivo | 在大鼠静脉血栓形成模型中，Zifaxaban 强烈抑制血栓形成，ED50 值为 3.09 mg/kg，其最佳疗效时间出现在给药后 2 小时[1]。在大鼠动静脉分流血栓形成和颈动脉血栓形成模型中，Zifaxaban 以剂量依赖性方式抑制血栓形成[1]。 |
| Name | Zifaxaban |
| CAS | 1378266-98-8 |
| Formula | C20H16ClN3O4S |
| Molar Mass | 429.88 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Qiu X, et al. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban. Eur J Pharmacol. 2018 Oct 5;836:50-56. |
Zifaxaban
CAS: 1378266-98-8 F: C20H16ClN3O4S W: 429.88
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human F
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.